- Home
- MGX
MGX
METAGENOMI INC
as 05-08-2025 4:00pm EST
Stocks
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 65.0M | IPO Year: | 2024 |
| Target Price: | $14.75 | AVG Volume (30 days): | 354.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.23 - $8.18 | Next Earning Date: | 05-16-2025 |
| Revenue: | $52,295,000 | Revenue Growth: | 16.84% |
| Revenue Growth (this year): | -38.37% | Revenue Growth (next year): | 6.95% |
Stock Insider Trading Activity of METAGENOMI INC (MGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wein Matthew | MGX | See Remarks | Mar 5 '25 | Sell | $1.87 | 930 | $1,743.56 | 9,467 | |
| Wapnick Pamela | MGX | Chief Financial Officer | Mar 5 '25 | Sell | $1.87 | 1,808 | $3,389.64 | 59,684 |
Latest METAGENOMI INC News
MGX Breaking Stock News: Dive into MGX Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Metagenomi to Present at Upcoming Scientific Meetings
Simply Wall St.
a month ago
Metagenomi Leads The Charge With These 3 Penny Stocks
TipRanks
a month ago
Biotech stocks slide as Marks resignation seen being negative for sector
Simply Wall St.
a month ago
Bullish: Analysts Just Made A Significant Upgrade To Their Metagenomi, Inc. (NASDAQ:MGX) Forecasts
MT Newswires
2 months ago
Chardan Adjusts Price Target on Metagenomi to $13 From $15, Keeps Buy Rating
GlobeNewswire
2 months ago
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
GlobeNewswire
2 months ago
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
Simply Wall St.
3 months ago
Alto Ingredients And 2 Other US Penny Stocks To Watch
Compare MGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGX METAGENOMI INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.